✨ Onyx Summary Phathom Pharmaceuticals clarified that an upcoming Schedule 13D filing by Frazier Life Sciences reflects only administrative reporting changes and does not reduce Frazier’s ownership in the company. By affirming that no shares have been sold, Phathom underscores continued investor commitment at a pivotal time in advancing its
✨ Onyx Summary ImmunityBio has launched a Phase 2 clinical trial to evaluate ANKTIVA®, its IL-15–based immunotherapy, in patients with long COVID, a condition affecting an estimated 1 in 5 U.S. adults after SARS-CoV-2 infection. The exploratory study will primarily assess safety, with secondary and exploratory measures including effects
✨ Onyx Summary Guardant Health announced the grant of 239,565 restricted stock units to 189 new employees and stock options for 23,542 shares to two additional hires under its 2023 Employment Inducement Incentive Award Plan. These equity awards not only serve as a material inducement for attracting top talent
✨ Onyx Summary Ocugen announced that the EMA’s CHMP has accepted the design of its ongoing Phase 2/3 GARDian3 trial of OCU410ST for Stargardt disease as sufficient to support both U.S. and European regulatory filings. Early Phase 1 data showed the therapy slowed lesion growth by 48% and
✨ Onyx Summary ImmunityBio reported early Phase I results from its QUILT-106 trial showing complete responses in the first two patients with relapsed Waldenström macroglobulinemia treated with its investigational CD19 CAR-NK therapy, given alone or with rituximab. Both heavily pretreated patients achieved remission without significant toxicities, and the therapy was delivered
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) – Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management
✨ Onyx Summary Belite Bio reported Q2 2025 results alongside key milestones: completion of enrollment in the Phase 3 PHOENIX trial in geographic atrophy, FDA Breakthrough Therapy Designation for Tinlarebant in Stargardt disease, and the DRAGON Phase 3 trial tracking to complete in Q4 2025. As of June 30, Belite had
✨ Onyx Summary ImmunityBio announced that the Michael E. DeBakey VA Medical Center in Houston has become one of the first VA hospitals in the U.S. to administer ANKTIVA®, its FDA-approved IL-15–based immunotherapy, to a veteran with bladder cancer. ANKTIVA is approved with BCG for patients with BCG-unresponsive non-muscle
✨ Onyx Summary Ocugen entered into a $20 million registered direct offering with Janus Henderson Investors, selling 20 million shares at $1.00 each along with warrants for another 20 million shares exercisable at $1.50. The warrants are valid for two years and callable if Ocugen’s stock trades above
✨ Onyx Summary Belite Bio entered a registered direct offering with a single large existing institutional shareholder to sell 230,770 ADSs and accompanying five-year warrants for another 230,770 ADSs at $65 per unit, for gross proceeds of about $15M (with up to an additional ~$15M possible upon warrant exercise)
✨ Onyx Summary Phathom Pharmaceuticals reported Q2 2025 net revenue of $39.5 million, up from $7.3 million a year earlier, driven by continued adoption of its acid blocker VOQUEZNA, which has surpassed 580,000 prescriptions. The company reduced operating expenses through restructuring and expects to achieve profitability in 2026,
✨ Onyx AI Summary The American Cancer Society announced a new partnership with Guardant Health to expand nationwide cancer screening initiatives, including public awareness campaigns, community-based interventions, and state-level coalition work to remove barriers to care. By combining ACS’s reach with Guardant’s innovation, the collaboration aims to close persistent
✨ Onyx Summary Verily announced the continuation of its partnership with Vanderbilt University Medical Center to support the NIH’s All of Us Research Program, extending its role in powering the Researcher Workbench platform that now serves over 17,000 researchers across 1,100 organizations worldwide. By enhancing secure, cloud-based access
✨ Onyx Summary Verily announced it has received a $14.7M grant from The Michael J. Fox Foundation to generate one of the most comprehensive molecular datasets for Parkinson’s disease, leveraging biospecimens and multimodal data from the Personalized Parkinson’s Project. By making this resource publicly available through its Workbench
✨ Onyx Summary Verily announced new institutions adopting its Workbench platform—including NashBio, the University of Oxford, and NIH’s CARD program—while rolling out enhanced tools for data governance, analysis, and discovery. As biomedical data grows exponentially, these expansions position Workbench as a key infrastructure for harnessing complex datasets, enabling
